Spatial Transcriptomic and Proteomic Analysis Identifies Novel Immune-Associated Biomarkers of Anti-PD1 Response in Metastatic Melanoma.

S A Koskela, R E Kallionpää, I Mäkelä, E-M Birkman, M Sundvall, C R Figueiredo

Abstract read

In one paragraph

Article in Scandinavian journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

S A KoskelaMedical Immuno-Oncology Research Group, Cancer Research Unit, Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.ORCID https://orcid.org/0000-0003-1870-7672

R E KallionpääAuria Biobank, Turku University Hospital, University of Turku, Turku, Finland.ORCID https://orcid.org/0000-0003-0146-0060

I MäkeläDepartment of Oncology, Turku University Hospital, Turku, Finland.ORCID https://orcid.org/0009-0009-9062-8363

E-M BirkmanLaboratory Division, Department of Pathology, Turku University Hospital, University of Turku, Turku, Finland.

M SundvallInstitute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.ORCID https://orcid.org/0000-0002-0494-2965

C R FigueiredoMedical Immuno-Oncology Research Group, Cancer Research Unit, Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.ORCID https://orcid.org/0000-0003-3680-4070

Funding

Academy of Finland 330876Academy of Finland 336530Academy of Finland 358209InFlames Flagship 337530InFlames Flagship 357910InFlames Flagship 358823Jane ja Aatos Erkon Säätiö 5957-12539Jane ja Aatos Erkon Säätiö 7180-2BD08Sigrid Juséliuksen Säätiö 220022Sigrid Juséliuksen Säätiö 230026Suomen Kulttuurirahasto 00240691Suomen Kulttuurirahasto 00260112Turku Doctoral Programme of Molecular MedicineTurun Yliopistosäätiö 081497

6 · The paper itself

Abstract

Resistance to anti-PD1 therapy remains a major challenge in metastatic melanoma, despite long-term benefit in some patients. Since a functional dendritic cell (DC)-CD8

Indexed as

Biomarkers, TumorMelanomaProgrammed Cell Death 1 ReceptorCD8-Positive T-LymphocytesDendritic CellsGene Expression Regulation, NeoplasticHumansNeoplasm MetastasisPrognosisProteomicsSpatial TranscriptomicsTranscriptomeTumor MicroenvironmentBiomarkers, TumorPDCD1 protein, humanProgrammed Cell Death 1 Receptoranti‐PD‐1 resistancemetastatic melanomaspatial transcriptomics

Identifiers

PMID42908204

DOI10.1111/sji.70153

PMCPMC13687651

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.